Zdrowie i gospodarka · 06/06/2016

FDA Extends Comment Period for Biosimilar Product Labeling Guidance

The Food and Drug Administration (FDA) is extending the comment period for its draft guidance on labeling for biosimilar products, allowing interested persons more time to submit comments, following the notice published in the Federal Register on April 4, 2016.